>

Investor Information



Intellectual Property for Glixin

December, 2019: A new patent application was filed with the USPTO.  Glixn trademark was published and we are currently pursuing a Registered Trademark.

February, 2018: The USPTO announced that the BLOS# patent application will be allowed and a patent issued in the coming weeks.

July 11, 2017: The USPTO announced that the CAT-FISH method will be an issued patent on July 25, 2017.  CAT-FISH is an example of another molecular biology based method co-invented and published in a peer-reviewed journal by Dr. Peter Stroot.  The RiboSyn method is another example of a novel molecular biology based method that was published and patented.

Glixin is offering an opportunity for companies to participate in forthcoming clinical trials.  Call John Kimber (720) 355-0446 for details. 


Glixin Meeting Information

March 16, 2017: Glixin (formerly HemaGnosis) has been invited to attend the 2017 BioBoot Camp Program April 20-21 in Denver, CO.


Glixin Annual Reports

2019 Annual Report


Pitch Deck

Glixin is currently seeking an investment of $3M to complete a clinical trial in Australia for the LifeStyle Choice BLOS# method.  A Pitch Deck is provided below.


Formula

 
Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


Formula


 



PASTE RESPONSIVE AD